OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

Abstract c-MET is considered a driver of cancer progression, impacting tumor growth and tumor-supporting stroma. Here, we investigated the therapeutic efficacy of OMO-1, a potent and selective c-MET inhibitor, in an immunocompetent intraductal mouse model for triple-negative breast cancer (TNBC). OM...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jonas Steenbrugge, Niels Vander Elst, Kristel Demeyere, Olivier De Wever, Niek N. Sanders, Wim Van Den Broeck, Eric Ciamporcero, Timothy Perera, Evelyne Meyer
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/b9aac903f53b496da8763625e4385c99
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares